For many researchers, progressing their research along the pathway to the clinic is challenging. This is particularly true of advanced therapies, including stem cell and gene therapy, CAR-T cells and oncolytic viruses, to name a few. These revolutionary approaches bring with them increased regulatory load, high costs, and the need for specialist cGMP facilities.
Bringing in a Contract Development and Manufacturing Organization (CDMO) as a partner can help to streamline and de-risk this process, making your research more attractive to funders and investors. In an exciting first for the LSRNW, we have speakers from two CDMOs who will talk about the benefits of working with them to realize your research goals.
Fujifilm Diosynth Biotechnologies (FDB) is an end to end CDMO, with facilities in the UK, USA and Denmark and with a wide-ranging expertise in the development of processes for pre-clinical, clinical and commercial manufacturing. Michael Baker and Katriina Makinen will present FDB’s capabilities and describe how a combination of toolbox and platform approaches can be used to speed up the delivery of research and clinical grade viral vectors for gene therapy. They will be on hand to answer your questions about how, as a CDMO partner, FDB can help you avoid common pitfalls, to efficiently progress your research to first in human trial and adding value to your project to attract investors.
In contrast, Stemmatters are a spin-out from the University of Minho, Portugal, and have extensive experience working with academic partners and assisting with sourcing grant funding for your project. Stemmatters CEO Rui A. de Sousa will be presenting, while Cristiana B. Cunha will be available to discuss your projects in the one-to-one sessions.
Register now to attend the webinar, and contact nrn@cardiff.ac.uk to book a 20min one-to-one slot with the company of your choice after the webinar. Slots will be available from 11.40am until 2pm on June 17th.
